<DOC>
	<DOC>NCT00209729</DOC>
	<brief_summary>To assess the usefulness of Docetaxel plus S-1 combination chemotherapy based on the antitumor effect and survival period by performing a phase I/II study of this combination in Elderly patients with inoperable or with postoperative gastric cancer.</brief_summary>
	<brief_title>Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.</brief_title>
	<detailed_description>A multicenter Open-label, single-arm, phase I/II clinical trial is conducted on Elderly patients with histological stage IV gastric cancer given Docetaxel plus S-1. The usefulness of this regimens as 1st line therapy for gastric cancer was evaluated by the disease-free survival rate (DFR), overall survival rate (OS), incidence and severity of adverse event.</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>1. Histological diagnosis of gastric adenocarcinoma. 2. Measurable or assessable lesions(Except for Phase I). 3. Age: 76 ~ 80 years. 4. Performance Status (ECOG): 0 ~ 2. 5. No prior chemotherapy or only one regimen of previous chemotherapy (with a washout period &gt;4 weeks after the final day of the previous therapy). Adjuvant chemotherapy is not defined as previous therapy. 6. No history of treatment with Docetaxel or S1. 7. No history of radiotherapy to the abdomen. 8. Oral intake of S1 is possible. 9. Adequate function of major organs (bone marrow, heart, lungs, liver etc.). WBC 3,500/mm3 and 12,000/mm3. Hb 10.0 g/dl. Platelet count 100,000/mm3. GOT and GPT 2.5 times the upper limit of normal (excluding liver metastasis). TBil 2.0mg/dl. Creatinine &lt;1.5 mg/dl (but if it is 1.0 ~ 1.5 mg/dl, the dose of S1 can be decreased according to the dose reduction criteria to allow registration in the trial). Normal ECG (not considering clinically unimportant arrhythmias and ischemic changes). 10. Predicted survival for &gt;3 months. 11. Able to give written informed consent. 1. Severe pleural effusion or ascites. 2. Metastasis to the central nervous system (CNS). 3. Active gastrointestinal bleeding. 4. Active infection. 5. Diarrhea (watery stools). 6. Uncontrolled ischemic heart disease. 7. Serious complications (such as intestinal paralysis, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, uncontrolled diabetes mellitus, heart failure, renal failure, or hepatic failure). 8. Active multiple cancer. 9. Severe mental disorder. 10. Pregnancy, possible pregnancy, or breastfeeding. 11. Flucytosine treatment. 12. Judged to be ineligible for this protocol by the attending physician.</criteria>
	<gender>All</gender>
	<minimum_age>76 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Docetaxel</keyword>
	<keyword>S-1</keyword>
	<keyword>Elderly Patients</keyword>
	<keyword>Gastric cancer</keyword>
</DOC>